SCHEMBL23692137

SCHEMBL23692137

CC(C)c1cc(OC(F)F)cc(C2CC2)c1CC(=O)N=S(N)(=O)c1ccc(CN(C)C)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 2/20 0.35
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
LMNA P02545 3/20 0.33
ALDH1A1 P00352 3/20 0.33
MAPT P10636 1/20 0.33
SMYD3 Q9H7B4 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
DAGLA Q9Y4D2 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
TRPM8 Q7Z2W7 1/20 0.31
BDKRB1 P46663 1/20 0.30
C5AR1 P21730 2/20 0.30
GPR183 P32249 1/20 0.30
ADGRF1 Q5T601 1/20 0.30
GPR65 Q8IYL9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20698839 0.90 NLRP3 (0.41) NLRP3LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL23692262 0.89 NLRP3 (0.33) NLRP3
SCHEMBL20698740 0.89 NLRP3 (0.31) NLRP3
SCHEMBL20698761 0.88 NLRP3 (0.39) NLRP3PSEN1PSEN2APH1BNCSTN
SCHEMBL20698690 0.88 NLRP3 (0.39) NLRP3PSEN1PSEN2APH1BNCSTN
SCHEMBL23692124 0.87 NLRP3 (0.38) NLRP3LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL25067028 0.85 NLRP3 (0.36) NLRP3PSEN1PSEN2APH1BNCSTN
SCHEMBL25066905 0.85 NLRP3 (0.36) NLRP3PSEN1PSEN2APH1BNCSTN
SCHEMBL22014337 0.85 NLRP3 (0.36) NLRP3PSEN1PSEN2APH1BNCSTN
SCHEMBL21893002 0.84 ALDH1A1 (0.34) NLRP3PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230079631-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-03-16 US disclosed
US-20230059136-A1 THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-02-23 US disclosed
US-11370763-B2 Compounds and compositions for treating conditions associated with NLRP activity NOVARTIS AG (CH) 2022-06-28 US disclosed
US-20210230129-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2021-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079631-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 NLRP3 2/4885PSEN1 2829/4885PSEN2 2624/4885
US-20210230129-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP3, NLRP1, IAPP NLRP3 1/4885PSEN1 227/4885PSEN2 171/4885
US-20230059136-A1 THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 NLRP3 2/4885PSEN1 2928/4885PSEN2 2768/4885
US-11370763-B2 Compounds and compositions for treating conditions associated with NLRP activity NLRP3, NLRP1, IAPP NLRP3 1/4885PSEN1 227/4885PSEN2 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.